US FDA patient-reported outcome guidance: great expectations and unintended consequences.
about
The Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration to Accelerate Diagnosis and Treatment of Traumatic Brain Injury.Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.Using qualitative methods in developing an instrument to identify barriers to self-care among persons with type 2 diabetes mellitus.Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Development of a multidimensional assessment tool for uraemic pruritus: Uraemic Pruritus in Dialysis Patients (UP-Dial).Development of the sporadic inclusion body myositis physical functioning assessment.The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.Why does quality of life remain an under-investigated issue in chronic kidney disease and why is it rarely set as an outcome measure in trials in this population?Assessing quality of life in Crohn's disease: development and validation of the Crohn's Life Impact Questionnaire (CLIQ).Clinical interpretation of the Uremic Pruritus in Dialysis Patients (UP-Dial) scale: a novel instrument for the assessment of uremic pruritus.Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in
P2860
Q36330425-5D981E7E-B7C8-4987-A964-BE3E433A151AQ37217253-C6116A51-8185-4210-A895-351FC977F473Q38293819-5BE3FAAF-A028-4B99-97B9-22A5A7FAA474Q38749061-BEA3CD29-0F7F-4F41-AA9D-1DC21F4D7DAAQ38778553-9135C9EF-D12C-4C98-86CF-B37F2349943CQ40000922-B9445A1D-A744-49CD-8783-E3D6F5421BB8Q47328182-01041A34-5DA9-4136-9E82-BA2F8E9D1B4FQ47574912-C87BED49-CE38-4B62-B957-971C6F03ED29Q47742192-05CFA3A2-9119-4318-A005-BCF578DDC15BQ48271594-F6166E95-4669-432C-A2DD-10A48F76EC46Q49361982-5F4495A1-21C5-4993-8E28-D8AD069DAE7C
P2860
US FDA patient-reported outcome guidance: great expectations and unintended consequences.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
US FDA patient-reported outcome guidance: great expectations and unintended consequences.
@en
type
label
US FDA patient-reported outcome guidance: great expectations and unintended consequences.
@en
prefLabel
US FDA patient-reported outcome guidance: great expectations and unintended consequences.
@en
P2093
P2860
P1476
US FDA patient-reported outcome guidance: great expectations and unintended consequences.
@en
P2093
Ari Gnanasakthy
Carla DeMuro
Cheryl Coon
Lori McLeod
Sheri Fehnel
P2860
P304
P356
10.1586/14737167.2013.814957
P577
2013-08-01T00:00:00Z